JP2005515981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005515981A5 JP2005515981A5 JP2003545329A JP2003545329A JP2005515981A5 JP 2005515981 A5 JP2005515981 A5 JP 2005515981A5 JP 2003545329 A JP2003545329 A JP 2003545329A JP 2003545329 A JP2003545329 A JP 2003545329A JP 2005515981 A5 JP2005515981 A5 JP 2005515981A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- terminus
- seq
- fcγr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000003852 Autoantibodies Human genes 0.000 claims 1
- 108090000206 Autoantibodies Proteins 0.000 claims 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Claims (9)
- 水溶液の形の医薬品組成物において、該医薬品組成物が真核または殊に原核の発現系からなる、組換えにより得られた可溶性のＦｃγＲ ＩＩｂまたはＦｃγＲ ＩＩＩを４０〜４０００ｍｇ、特に１００〜１０００ｍｇの量および５０ｍｇ／ｍｌまでの濃度で含有し、場合によっては他の製薬学的に認容性の助剤および／または担持剤を含有することを特徴とする、水溶液の形の医薬品組成物。
- 前記医薬品組成物が注射溶液の形で存在する、請求項１記載の医薬品組成物。
- 前記医薬品組成物がＳＥＱ ＩＤ ＮＯ．１に記載のＦｃγＲ ＩＩｂを含有するかまたは野生型の蛋白質の適当な配列を有するＮ末端および／またはＣ末端で延長された、有利にＳＥＱ ＩＤ ＮＯ．３に記載の形を含有する、請求項１または２記載の医薬品組成物。
- 前記医薬品組成物がＳＥＱ ＩＤ ＮＯ．２に記載のＦｃγＲ ＩＩＩを含有するかまたは野生型の蛋白質の適当な配列を有するＮ末端および／またはＣ末端で延長された、有利にＳＥＱ ＩＤ ＮＯ．４に記載の形を含有する、請求項１または２記載の医薬品組成物。
- 過剰の免疫反応および抗体、殊に自己抗体の病的に増殖された形成によって惹起された疾病または状態を治療するための請求項１から４までのいずれか１項に記載の医薬品組成物。
- 多発性硬化症、全身性紅斑性狼そう、リウマチ様関節炎または高められた数のＮＫ細胞に付随して現れる疾病の治療のための請求項５記載の医薬品組成物。
- ＦｃγＲ ＩＩｂを含有する医薬品組成物が使用されている、請求項５または６記載の医薬品組成物。
- 過剰の免疫反応の結合のためにＦｃγＲ ＩＩＩが使用されている、請求項５記載の医薬品組成物。
- 注射のための、請求項５から８までのいずれか１項に記載の医薬品組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10157290.5 | 2001-11-22 | ||
| DE10157290A DE10157290A1 (de) | 2001-11-22 | 2001-11-22 | Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III |
| PCT/EP2002/013080 WO2003043648A2 (de) | 2001-11-22 | 2002-11-21 | Sfcyr iib oder sfcyr iii für die behandlung von autoimmunkrankheiten |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005515981A JP2005515981A (ja) | 2005-06-02 |
| JP2005515981A5 true JP2005515981A5 (ja) | 2006-01-19 |
| JP5414959B2 JP5414959B2 (ja) | 2014-02-12 |
Family
ID=7706571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003545329A Expired - Lifetime JP5414959B2 (ja) | 2001-11-22 | 2002-11-21 | ｓＦｃγＲＩＩｂまたはｓＦｃγＲＩＩＩを含有する医薬品組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20050002924A1 (ja) |
| EP (1) | EP1446139B1 (ja) |
| JP (1) | JP5414959B2 (ja) |
| AT (1) | ATE409045T1 (ja) |
| AU (1) | AU2002366200A1 (ja) |
| CA (1) | CA2506068C (ja) |
| CO (1) | CO5590936A2 (ja) |
| DE (2) | DE10157290A1 (ja) |
| ES (1) | ES2309238T3 (ja) |
| WO (1) | WO2003043648A2 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1709073E (pt) | 2003-11-26 | 2011-09-29 | Max Planck Gesellschaft | Substância que se liga ao receptor fc iib de igg humano (fcgamariib) |
| US10669324B2 (en) | 2012-10-30 | 2020-06-02 | Suppremol Gmbh | Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein |
| ES2625044T3 (es) | 2012-10-30 | 2017-07-18 | Suppremol Gmbh | Una composición farmacéutica para su uso en el tratamiento o prevención de una enfermedad inflamatoria o una enfermedad autoinmunitaria, o ambas |
| US10028998B2 (en) * | 2012-10-30 | 2018-07-24 | Suppremol Gmbh | Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb |
| AU2012244302B2 (en) * | 2012-10-31 | 2014-08-21 | Suppremol Gmbh | A method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease |
| EP2796144A1 (en) | 2013-04-26 | 2014-10-29 | SuppreMol GmbH | Highly concentrated Formulations of soluble Fc receptors |
| EP2833139A1 (en) * | 2013-08-01 | 2015-02-04 | SuppreMol GmbH | In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s) |
| EP2837637A1 (en) | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
| JP6893223B2 (ja) * | 2013-10-16 | 2021-06-23 | ズプレモル ゲーエムベーハー | 医薬品組成物およびキット |
| EA034176B1 (ru) * | 2013-10-16 | 2020-01-14 | Зуппремоль Гмбх | РАСТВОРИМЫЙ Fc-ГАММА РЕЦЕПТОР ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ БУЛЛЕЗНЫХ ЗАБОЛЕВАНИЙ |
| JP2018050616A (ja) | 2016-09-23 | 2018-04-05 | 東ソー株式会社 | 改良型組換えＦｃγＲＩＩ |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010024899A (ko) * | 1998-02-06 | 2001-03-26 | 일렉서스 피티와이 리미티드 | Ｆｃ 수용체의 삼차원 구조 및 모델 및 그의 용도 |
| EP1006183A1 (en) * | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| EP1201681A1 (en) * | 2000-10-30 | 2002-05-02 | Millennium Pharmaceuticals, Inc. | "Fail" molecules and uses thereof |
-
2001
- 2001-11-22 DE DE10157290A patent/DE10157290A1/de not_active Withdrawn
-
2002
- 2002-11-21 AU AU2002366200A patent/AU2002366200A1/en not_active Abandoned
- 2002-11-21 ES ES02803402T patent/ES2309238T3/es not_active Expired - Lifetime
- 2002-11-21 AT AT02803402T patent/ATE409045T1/de active
- 2002-11-21 DE DE50212814T patent/DE50212814D1/de not_active Expired - Lifetime
- 2002-11-21 JP JP2003545329A patent/JP5414959B2/ja not_active Expired - Lifetime
- 2002-11-21 CA CA2506068A patent/CA2506068C/en not_active Expired - Lifetime
- 2002-11-21 EP EP02803402A patent/EP1446139B1/de not_active Expired - Lifetime
- 2002-11-21 WO PCT/EP2002/013080 patent/WO2003043648A2/de active IP Right Grant
-
2004
- 2004-05-24 US US10/851,655 patent/US20050002924A1/en not_active Abandoned
- 2004-06-18 CO CO04057552A patent/CO5590936A2/es not_active Application Discontinuation
-
2008
- 2008-01-09 US US11/971,438 patent/US20080214459A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chorev | The partial retro–inverso modification: a road traveled together | |
| ES2316154T3 (es) | Peptidos cationicos antimicrobianos y procedimientos de seleccion de los mismos. | |
| Efimov | A novel super-secondary structure of proteins and the relation between the structure and the amino acid sequence | |
| TW464656B (en) | Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease | |
| JP2005515981A5 (ja) | ||
| Carrington et al. | Implications of conserved structural motifs in disparate trypanosome surface proteins | |
| WO2002043661B1 (en) | Recombinant anti-cd30 antibodies and uses thereof | |
| JPH06504192A (ja) | ポリペプチドおよびその使用 | |
| WO2001083527A3 (en) | Glucagon antagonists | |
| JPH07508025A (ja) | インスリン様増殖因子（ｉｇｆ−１）類似体 | |
| JP2017527272A5 (ja) | ||
| CA2579798A1 (en) | Interleukin-15 antagonist peptide | |
| JP2010534486A5 (ja) | ||
| US5891679A (en) | TNF-alpha muteins and a process for preparing them | |
| NO327080B1 (no) | Syntetisk opioidpeptidamid samt et farmasoytisk preparat | |
| KR920019820A (ko) | 히브리드 폴리펩티드 조성물, 히브리드 폴리펩티드의 제조방법 및 이를위한 dna 발현벡터 | |
| JP2002514418A5 (ja) | ||
| EP2343318A3 (en) | Antibodies binding to a C-terminal fragment of apolipoprotein E | |
| RU2005126236A (ru) | Фьюжн-белок для подавления цервикального рака | |
| WO1999060013A3 (en) | Il-6 antagonist peptides | |
| IL106271A (en) | Ligand to TNF 75P receptor and its preparation | |
| KR20240005777A (ko) | Hras 및 nras에 대해서 선택적인 kras 저해 작용을 갖는 환상 화합물 | |
| Griggs et al. | The N-terminus and C-terminus of IFN-gamma are binding domains for cloned soluble IFN-gamma receptor. | |
| KR980002066A (ko) | 변이형 인간 성장호르몬 및 그의 용도 | |
| CA2506068A1 (en) | Pharmaceutical composition containing sfcyr iib or sfcyr iii |